劳拉替尼治疗携带ALK或ROS1基因重排非小细胞肺癌患者的首项全球多中心非盲单臂临床试验

    The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement

    /

    返回文章
    返回